Proteomic risk scores can help identify high-risk patients and monitor short- and long-term effects of treatment
Proteomic risk scores can help identify high-risk patients and monitor short- and long-term effects of treatment
A webinar presented by Clare Paterson, PhD, Associate Director of Clinical Research, SomaLogic, and Jessica Chadwick, PhD, Scientist, SomaLogic
Abstract
In this 1-hour discussion, you will learn how large-scale proteomics can be leveraged for multiple applications in the field of oncology. The focus will be on two new avenues of oncology research. The first is using proteomic risk scores to monitor the cardiotoxic effects of anthracycline treatment and identify patients who may benefit from cardioprotective therapy. The other is developing blood-based protein tests for stratifying lung cancer susceptibility. From biomarker discovery to medicine application and the potential to inform and impact patients’ standard of care—there is a lot to learn and look forward to in oncology research using proteomics.
Clare Paterson, PhD
Associate Director of Clinical Research, SomaLogic
Prior to SomaLogic, Dr. Paterson conducted a fellowship in the clinical brain disorders branch at the National Institutes of Health (NIH) before becoming an Assistant Professor in Psychiatry at the University of Colorado School of Medicine.
Her academic research career focused on the use of -omics technologies to map how the human brain develops and ages and is altered in psychiatric illnesses, with the aim of ultimately uncovering new means of patient stratification and treatment discovery.
Jessica Chadwick, PhD
Scientist, SomaLogic
Dr. Jessica Chadwick is a scientist in the Clinical Research & Development department at SomaLogic. She completed her PhD in biochemistry at The Ohio State University as an NIH fellow. Her academic research focused on novel therapeutic strategies for treating Duchenne muscular dystrophy.
Dr. Chadwick has worked at SomaLogic for over 5 years on the development and productization of proteomic-based cardiometabolic tests. More recently she led an exciting new body of work aimed at assessing the robustness and sensitivity of these tests to interventions.
Protein biomarker models for oncology risk assessment and treatment monitoring
A webinar presented by Clare Paterson, MD, and Jessica Chadwick, MD
Contact us to learn more today
More webinars
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched healthy controls.
WebinarData Summit 2025
Take your research further with expert insights from the SomaScan™ Data Summit. Explore the latest platform updates, advanced data analysis tools, and innovative applications for SOMAmer™ reagents. From optimizing sample quality to customizing panels beyond 7K and 11K, this event is packed with knowledge to help you get the most from your data.